NeuroSense Therapeutics (NRSN)
(Delayed Data from NSDQ)
$1.20 USD
+0.08 (6.96%)
Updated May 15, 2024 03:59 PM ET
After-Market: $1.20 0.00 (0.17%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
NRSN 1.20 +0.08(6.96%)
Will NRSN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NRSN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for NRSN
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning
NeuroSense Optimizes ALS Trial with Machine Learning
NeuroSense partners with PhaseV for machine learning in ALS Phase 3 trial
NeuroSense files to sell 3.05M ordinary shares for holders
NeuroSense’s PrimeC Shows Promise in ALS Trial